New molecular targets in melanoma

被引：17

作者：

Flaherty, KT ^{[1
]}

Brose, MS ^{[1
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

CURRENT OPINION IN ONCOLOGY | 2004年 / 16卷 / 02期

关键词：

melanoma; molecular targets; metastasis;

D O I：

10.1097/00001622-200403000-00012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic melanoma remains a disease with few therapeutic options and no regimen that prolongs survival. Peptide and whole-cell vaccines that use cell surface proteins unique to melanoma to engender a specific immune response have not been associated with significant antitumor activity in patients with unresectable metastatic disease. The commonly used chemotherapeutic agents have limited efficacy and do not capitalize on abnormalities that are unique to melanoma [1]. Therapies that target the molecular pathophysiology of metastatic melanoma provide hope that more effective treatments will soon be available.

引用

页码：150 / 154

页数：5

共 32 条

[11]

FLAHERTY KT, 2003, P AN M AM SOC CLIN, V22, P710

[12] Phase II study of paclitaxel and carboplatin for malignant melanoma [J].

Hodi, FS ;

Soiffer, RJ ;

Clark, J ;

Finkelstein, DM ;

Haluska, FG .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (03) :283-286

[13] Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma [J].

Hwu, WJ ;

Krown, SE ;

Menell, JH ;

Panageas, KS ;

Merrell, J ;

Lamb, LA ;

Williams, LJ ;

Quinn, CJ ;

Foster, T ;

Chapman, PB ;

Livingston, PO ;

Wolchok, JD ;

Houghton, AN .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3351-3356

[14] Chemosensitisation of malignant melanoma by BCL2 antisense therapy [J].

Jansen, B ;

Wacheck, V ;

Heere-Ress, E ;

Schlagbauer-Wadl, H ;

Hoeller, C ;

Lucas, T ;

Hoermann, M ;

Hollenstein, U ;

Wolff, K ;

Pehamberger, H .

LANCET, 2000, 356 (9243) :1728-1733

[15] A CELL-CYCLE REGULATOR POTENTIALLY INVOLVED IN GENESIS OF MANY TUMOR TYPES [J].

KAMB, A ;

GRUIS, NA ;

WEAVERFELDHAUS, J ;

LIU, QY ;

HARSHMAN, K ;

TAVTIGIAN, SV ;

STOCKERT, E ;

DAY, RS ;

JOHNSON, BE ;

SKOLNICK, MH .

SCIENCE, 1994, 264 (5157) :436-440

[16] Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial [J].

Karp, JE ;

Lancet, JE ;

Kaufmann, SH ;

End, DW ;

Wright, JJ ;

Bol, K ;

Horak, I ;

Tidwell, ML ;

Liesveld, J ;

Kottke, TJ ;

Ange, D ;

Buddharaju, L ;

Gojo, I ;

Highsmith, WE ;

Belly, RT ;

Hohl, RJ ;

Rybak, ME ;

Thibault, A ;

Rosenblatt, J .

BLOOD, 2001, 97 (11) :3361-3369

[17] Tumor vascularity in the prognostic assessment of primary cutaneous melanoma [J].

Kashani-Sabet, M ;

Sagebiel, RW ;

Ferreira, CMM ;

Nosrati, M ;

Miller, JR .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1826-1831

[18]

MALDONADO JL, 2003, P AACR, P44

[19]

O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977

[20]

Peralba JM, 2003, CLIN CANCER RES, V9, P2887

← 1 2 3 4 →